SCHEMBL714399

SCHEMBL714399

Cc1ccc(-c2[c]cccc2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.54
CCR5 P51681 1/20 0.54
CCR8 P51685 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
CYP3A4 P08684 1/20 0.43
CYP2A6 P11509 1/20 0.43
METAP2 P50579 1/20 0.41
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
FAAH O00519 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
CYP1A2 P05177 1/20 0.32
PIM1 P11309 1/20 0.31
GRM5 P41594 2/20 0.31
RAB9A P51151 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28688434 0.78 MEN1 (0.33) RAB9AMEN1NPC1KMT2AGRIN2D
SCHEMBL28590403 0.76 NPC1 (0.39) RAB9ANPC1
SCHEMBL18422776 0.74 EGLN2 (0.43) GRM5KDM4EALDH1A1PDE10A
SCHEMBL3911683 0.74 CCR1 (0.48) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL1521688 0.73 APLNR (0.31) RAB9ANPC1KDM4EALDH1A1
SCHEMBL8503514 0.73 CCR1 (0.55) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL28852322 0.73 CCR1 (0.52) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL715526 0.73
SCHEMBL37815 0.72 KDM4E (0.54) CCR1CCR5CCR8CYP2A6METAP2
Abametapir SCHEMBL351152 0.72 CCR1 (1.00) CCR1CCR5CCR8HDAC6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928875-B1 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same NOVARTIS AG (CH) 2011-06-29 EP claimed
CN-101983191-A Oxim derivatives as hsp90 inhibitors TAKEDA PHARMACEUTICAL 2011-03-02 CN claimed
EP-2252595-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP claimed
US-7671059-B2 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones NOVARTIS AG (CH) 2010-03-02 US claimed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US claimed
WO-2009097578-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-08-06 WO claimed
CN-101287734-A 2-amino-7, 8-dihydro-6H-pyrido [4, 3-d ] pyrimidin-5-ones NOVARTIS AG (CH) 2008-10-15 CN claimed
EP-1928875-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES Novartis AG (CH) 2008-06-11 EP claimed
CN-101198596-A 2-amino-quinaz0lin-5-ones as HSP90 inhibitors useful in treating proliferation diseases NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-06-11 CN claimed
EP-1885701-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES Novartis Vaccines and Diagnostics, Inc. (US) 2008-02-13 EP claimed
US-20070123546-A1 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones CHIRON CORPORATION 2007-05-31 US claimed
WO-2007041362-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES NOVARTIS AG (CH) 2007-04-12 WO claimed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 US claimed
WO-2006113498-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-10-26 WO claimed
CN-109311844-B Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component 东曹株式会社 2021-07-20 CN disclosed
CN-112912372-A Cyclic azine compound, material for organic electroluminescent element, electron transport material for organic electroluminescent element, and organic electroluminescent element 东曹株式会社 2021-06-04 CN disclosed
WO-2020085319-A1 CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ELECTRON TRANSPORT MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT 東ソー株式会社 2020-04-30 WO disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 US disclosed
WO-2006113498-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-10-26 WO disclosed
EP-0441718-A1 Herbicidally active triazolopyridine compounds RHONE-POULENC AGROCHIMIE (FR) 1991-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CCR1 4594/4885CCR5 4279/4885CCR8 4528/4885
US-20070123546-A1 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones TYMP, TPMT, TYMS CCR1 486/4885CCR5 449/4885CCR8 96/4885
US-20070027150-A1 2-Amino-quinazolin-5-ones TK1, TK2, SLC1A5 CCR1 2070/4885CCR5 1229/4885CCR8 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.